- Trial Phase
- Approved
- Time to Market
- Already approved and marketed since 2014. A subcutaneous formulation is in Phase 1b/2 trials and would require additional FDA review if successful.
- Why 4/10
- BLINCYTO is already approved and commercially marketed with no pending PDUFA date or pivotal readout in the next 12 months. It is one of many products in Amgen's large, diversified pipeline (2025 total revenue $36.75B, BLINCYTO contributed ~$1.56B or about 4%). The subcutaneous formulation is early-stage (Phase 1b/2) and not a near-term binary catalyst. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
BLINCYTO has no near-term binary catalyst. Watch for quarterly sales growth trends as a proxy for adoption into earlier treatment lines, and for any data updates on the subcutaneous formulation at 2027 medical conferences. The key long-term risk is the 2029 US exclusivity cliff, but that is more than two years away. For Amgen as a whole, BLINCYTO is a steady growth contributor within a much larger, diversified portfolio.
Price Chart
Executive Summary
BLINCYTO (blinatumomab) is Amgen's first-in-class bispecific T-cell engager (BiTE) immunotherapy for B-cell acute lymphoblastic leukemia (ALL). First approved in 2014, it has expanded through multiple label updates, most recently in June 2024 for consolidation-phase treatment. The drug generated approximately $1.56 billion in 2025 sales (28% year-over-year growth), driven by volume expansion into earlier treatment lines and pediatric populations. Recent Phase 3 data (AALL1731, AIEOP-BFM ALL 2017) continue to support its use in newly diagnosed patients. No biosimilars are approved as of late 2026, though US exclusivity is estimated through early 2029. For Amgen, BLINCYTO is a meaningful growth product but represents a small fraction of a $36.75 billion revenue base, limiting its company-level stock impact.
How It Works
BLINCYTO is a bispecific T-cell engager (BiTE) antibody that works like a molecular bridge. One end grabs onto a patient's own immune T cells (via the CD3 receptor) and the other end grabs onto cancer B cells (via the CD19 protein). This forces the T cell to kill the cancer cell. It is given as a continuous intravenous infusion over 28 days via a portable pump.
Trial Status
BLINCYTO was first FDA-approved in December 2014 (accelerated) for relapsed/refractory B-cell ALL. It received full approval in July 2017 based on the Phase 3 TOWER study showing overall survival benefit. The FDA approved its latest label expansion in June 2024 for consolidation-phase treatment of CD19-positive, Philadelphia chromosome-negative B-ALL in adults and children one month or older. Multiple Phase 3 trials have since reported positive results: the AALL1731 trial (December 2024) showed adding BLINCYTO to chemotherapy yielded 96% three-year disease-free survival in pediatric standard-risk B-ALL; the AIEOP-BFM ALL 2017 trial (September 2026, NEJM) showed replacing chemotherapy with BLINCYTO improved outcomes in high-risk pediatric ALL with fewer infections. A subcutaneous formulation is in Phase 1b/2 trials to replace the burdensome continuous IV infusion.
The Two-Sided Case
Upcoming Catalysts
- No hard-dated PDUFA or pivotal readout is scheduled in the next 12 months for the approved IV formulation. The subcutaneous formulation (Phase 1b/2) could produce interim data updates at medical conferences in 2027, but no specific date is set.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report